Literature DB >> 24722159

ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.

Anna Caliò1, Alessia Nottegar, Eliana Gilioli, Emilio Bria, Sara Pilotto, Umberto Peretti, Stefania Kinspergher, Francesca Simionato, Serena Pedron, Sakari Knuutila, Giampaolo Tortora, Albino Eccher, Antonio Santo, Luca Tondulli, Giorgio Inghirami, Fabrizio Tabbò, Guido Martignoni, Marco Chilosi, Aldo Scarpa, Matteo Brunelli.   

Abstract

INTRODUCTION: The report of cases of lung squamous cell cancers harboring anaplastic lymphoma kinase (ALK) gene rearrangements raises the question whether this histologic subtype should be also evaluated for such molecular predictive test.
METHODS: A consecutive series of 40 lung pure squamous cell carcinomas were analyzed for ALK gene status by fluorescence in situ hybridization. Squamous differentiation was validated using an immunohistochemical panel including n-p63 (p40), cytokeratin (CK) 5/6, sex-determining region Y (SRY)-Box2 (SOX2), thyroid transcription factor 1, CK7, and Napsin-A.
RESULTS: Squamous differentiation was confirmed in all tumors as they stained positive for n-p63 and CK5/6 and negative for thyroid transcription factor 1 and Napsin-A. One of 40 cases (2.5%) showed an ALK rearrangement on fluorescence in situ hybridization analysis.
CONCLUSIONS: ALK translocation may be found in lung pure squamous cell carcinomas. Our data suggest the opportunity to test ALK rearrangements on biopsy samples harboring squamous cell cancer differentiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722159     DOI: 10.1097/JTO.0000000000000109

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  ALK-rearranged squamous cell lung cancer: a case report.

Authors:  Quan Zhang; Jinghui Wang; Shucai Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda; Hiroki Kishima
Journal:  Mol Clin Oncol       Date:  2016-04-26

3.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Yusuke Takanashi; Shogo Tajima; Shun Matsuura; Shin Koyama; Tsuyoshi Takahashi; Hiroshi Neyatani
Journal:  Respirol Case Rep       Date:  2015-07-02

Review 4.  Promising targets and current clinical trials in metastatic squamous cell lung cancer.

Authors:  Mark D Vincent
Journal:  Front Oncol       Date:  2014-12-09       Impact factor: 6.244

Review 5.  Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Authors:  Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen
Journal:  J Pers Med       Date:  2016-01-15

6.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

7.  Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib.

Authors:  Liping Lin; Fuxi Huang; Fang Chen; Yan He; Jiazhu Hu; Xiaolong Cao
Journal:  J Int Med Res       Date:  2018-01-08       Impact factor: 1.671

8.  Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature.

Authors:  Xin Yang; Ping Peng; Li Zhang
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

Review 9.  Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective.

Authors:  Elisa Brega; Guilherme Brandao
Journal:  Front Oncol       Date:  2014-07-16       Impact factor: 6.244

10.  Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Authors:  Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.